John F. Crowley - 03 Sep 2021 Form 4 Insider Report for AMICUS THERAPEUTICS, INC. (FOLD)

Role
Chairman & CEO, Director
Signature
/s/ Christian Formica, Attorney-in-Fact
Issuer symbol
FOLD
Transactions as of
03 Sep 2021
Net transactions value
-$43,381
Form type
4
Filing time
08 Sep 2021, 18:45:06 UTC
Previous filing
07 Sep 2021
Next filing
17 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FOLD Common Stock Options Exercise $5,429 +1,538 +0.18% $3.53 841,383 03 Sep 2021 Direct
transaction FOLD Common Stock Options Exercise $14,134 +3,700 +0.44% $3.82 845,083 03 Sep 2021 Direct
transaction FOLD Common Stock Sale $62,944 -5,238 -0.62% $12.02 839,845 03 Sep 2021 Direct F1, F2
holding FOLD Common Stock 64,895 03 Sep 2021 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FOLD Stock Options (right to buy) Options Exercise $0 -1,538 -100% $0.000000* 0 03 Sep 2021 Common Stock 1,538 $3.53 Direct F3
transaction FOLD Stock Options (right to buy) Options Exercise $0 -3,700 -12% $0.000000 27,739 03 Sep 2021 Common Stock 3,700 $3.82 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.00 to $12.08 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 All of these options were fully vested and exercisable as of the transaction date.